Association of Cardiovascular Disease, Respiratory Diseases, and Diabetes Treatment With COVID-19 Mortality in Hospitalized Patients

Abstract

Background: The prevalence of the coronavirus disease 2019 (COVID-19) in patients with preexisting non-communicable disease was high, and there was a question regarding the effect of the usage of medications on COVID-19 outcomes in these patients. Therefore, this study investigated the outcome of patients with different cardiovascular diseases (CVDs), respiratory diseases, and diabetes drug use. Methods: In this analytical longitudinal study, information was collected on clinical laboratory data, COVID-19 severity, comorbidities, and drug use. The follow-up time was from enrollment to discharge or death. Results: A total of 1046 hospitalized patients with COVID-19 participated in this analytical longitudinal study. The most commonly used drugs were CVD drugs (39.4%) and diabetes drugs (19.7%). The frequency of drug use was statistically similar between survivors and non-survivors except for diabetic drug use which was significantly higher in non-survivors (P=0.04). Patients who used the diabetic drugs were more likely to die (odds ratio [OR]: 1.41, 95% CI: 1.008-1.97). Moreover, the association was not significant after adjusting to confounding factors, and there was no significant association between other drug use and death in patients with COVID-19. Conclusion: The result of the present study showed that antihypertensive treatments, antidiabetic, and respiratory disease drugs were not associated with higher deaths in hospitalized patients with COVID-19.